Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus

BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contrib...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Gut Liver
Päätekijät: Tamai, Hideyuki, Ida, Yoshiyuki, Kawashima, Akira, Shingaki, Naoki, Shimizu, Ryo, Moribata, Kosaku, Nasu, Tetsushi, Maekita, Takao, Iguchi, Mikitaka, Kato, Jun, Nakao, Taisei, Kitano, Masayuki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Editorial Office of Gut and Liver 2017
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5491091/
https://ncbi.nlm.nih.gov/pubmed/28506030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl16525
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia